
News|Articles|February 28, 2025
Executive Summary: Leveraging the Evolving Bioequivalence Regulatory Landscape to Enhance Inhaled Product Design and Development
Author(s)Vectura Group plc, Vectura
The regulatory landscape for bioequivalence continues to evolve, leveraging a broader suite of characterization techniques. These not only provide deeper product understanding, but also utility for generic product development as the potential for replacement of costly clinical studies becomes more of a reality.
Trending on Pharmaceutical Technology
1
European Biotechs Reshaping Respiratory Disease
2
Midyear 2026 Industry Report: Taking Stock of Pharma Manufacturing, AI, and Regulatory Trends
3
GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy
4
Six Months In: A 2026 Progress Check on Pharma Manufacturing, AI, and Regulatory Shifts
5